NRI from all over the world (excluding U.S.A. & Canada) can invest in this fund
SBNRI is a certified Mutual Fund distributor registered with Association of Mutual Funds in India (AMFI) with Reg. No. 246671
₹16.30
-4.65%
NAV as on 16 Jan 25, 12:00 AM
very high risk
sector healthcare
equity
NAV as on 16 Jan 25, 12:00 AM
very high risk
sector healthcare
equity
41.15%p.a.
Last 1Y
20.11%p.a.
Last 3Y
0.00%p.a.
Last 5Y
19.20%p.a.
Since Inception
About ITI Pharma and Healthcare Fund Reinvestment Inc Dist cum Cap Wdrl for NRIs
NRIs can achieve long-term capital appreciation by investing in the ITI Pharma and Healthcare Fund Reinvestment Inc Dist cum Cap Wdrl scheme from ITI Asset Management Limited. It is a Sector - Healthcare mutual fund scheme that predominantly invests in Sector - Healthcare stocks of companies. Launched on Nov 2021, ITI Pharma and Healthcare Fund Reinvestment Inc Dist cum Cap Wdrl is Sector - Healthcare fund of its category with 217.92 Cr fund under management as on Jan 2025. The expense ratio of this fund is less than that of most other Fund category Sector - Healthcare funds.
- ITI Pharma and Healthcare Fund Reinvestment Inc Dist cum Cap Wdrl delivered 41.1% annual returns during the last year. It has delivered 19.2% average annual returns since the fund was launched.
- ITI Pharma and Healthcare Fund Reinvestment Inc Dist cum Cap Wdrl scheme tends to consistently deliver higher returns than most schemes in the same category.
- The scheme has predominantly invested in equity
Fund Objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Top 10 Holdings
Sun Pharmaceuticals Industries Ltd
15.23%
Lupin Ltd
6.02%
Suven Pharmaceuticals Ltd
5.76%
Aurobindo Pharma Ltd
4.85%
Divi's Laboratories Ltd
4.77%
Apollo Hospitals Enterprise Ltd
4.75%
Torrent Pharmaceuticals Ltd
3.70%
Max Healthcare Institute Ltd Ordinary Shares
3.53%
Laurus Labs Ltd
3.20%
Syngene International Ltd
2.71%
Fund Managers
- Dhimant Shah (Dec 2022 - Present)
- Rohan Korde (Nov 2021 - Present)
Key Information
View Scheme Document
ITI Pharma and Healthcare Fund Reinvestment Inc Dist cum Cap Wdrl SIP Calculator
If invested
per month
For a period of
Investment of ₹0 could have been
₹0(+0.0%)
₹0 (+0.0%)
This Fund
₹0 (+0.0%)
Fixed Deposit
NRI Mutual Fund Tax on ITI Pharma and Healthcare Fund Reinvestment Inc Dist cum Cap Wdrl
Just like for resident investors, capital gains from mutual fund investments are subject to income tax for NRI investors.
| Fund Type | Short-term Capital Gains (STCG) Tax | Long-term Capital Gains (LTCG) Tax |
|---|---|---|
| Equity mutual funds | 15% | 10% (above Rs. 1 lakh LTCG) without indexation* |
| Debt & other types of funds | At tax slab rate | 20% with indexation benefits |
How can NRIs invest in ITI Pharma and Healthcare Fund Reinvestment Inc Dist cum Cap Wdrl?
NRIs and OCIs can download the SBNRI app to invest in mutual funds from the country of their residence. Here are a few simple steps you need to take:
- Complete your NRI KYC: Type in your personal details and attach supporting documents, like:
- PAN Number
- Overseas address proof: Any of – Water/electricity bill, postpaid mobile/internet bill, rent agreement, driving license, etc.
- Passport – front and back
- Passport size photograph
- signature
If all details are correct, your KYC will be approved within 7 to 8 business days.
- Onboarding: After KYC, you need to share the following details to complete onboarding process and start investing in ITI Pharma and Healthcare Fund Reinvestment Inc Dist cum Cap Wdrl
- Onboarding: After KYC, you need to share the following details to complete onboarding process and start investing:
- City and country of birth
- NRE/NRO bank account statement/ canceled cheque for the latest 3 months
- Nominee details
Similar Funds
Funds
3Y Return
Nippon India Pharma Fund - Bonus
very high risk | equity
19.9%
Nippon India Pharma Fund Payout Inc Dist cum Cap Wdrl
very high risk | equity
21.3%
Nippon India Pharma Fund - Growth
very high risk | equity
19.9%
Frequently Asked Questions
Copyright | 2021 @ SBNRI | All Rights Reserved